MorphoSys AG (NASDAQ:MOR) Q2 2020 Earnings Conference Call - Final Transcript
Aug 06, 2020 • 08:00 am ET
Ladies and gentlemen, welcome to the MorphoSys Half Year Report 2020 Conference Call. [Operator Instructions]
Now I would like to turn the conference over to Anja Pomrehn. Please go ahead.
Thank you. Ladies and gentlemen, good afternoon or good morning. My name is Anja Pomrehn, Head of Investor Relations at MorphoSys. It's my pleasure to welcome you to our Q2 2020 results conference call and webcast. With me on the call today are Jean-Paul Kress, Chief Executive Officer; Jens Holstein, Chief Financial Officer; Malte Peters, Chief Research and Development Officer; and Roland Wandeler, Chief Operating Officer. Before we start, I would like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding our expectations for the commercialization of our products and our development plans, the impact of COVID-19 on our business and expectations for the compounds in our pipeline as well as the development plans of our collaboration partners.
These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ material, including those described in MorphoSys 20-F and annual report or for the year ended December 31, 2019, and from time to time in other SEC documents of MorphoSys. It is important to keep in mind that our statements on this webcast speak as of today. Readers and listeners are requested to refer to slide two. You will find the agenda of today's call on slide three. Jean-Paul will provide an overview of the highlights in the second quarter 2020. Jens, then will talk you through the financial results of both the second and the first half of 2020 before Jean-Paul will close with a summary. After the presentation, we will be available for your questions. The presentation as well as the media release announcing the Q2 and H1 2020 results are available on MorphoSys' corporate website, morphosys.com.
I'll now hand over to Jean-Paul.
Thank you, Anja. Good morning or good afternoon, everyone. I would like to take the opportunity to introduce Roland Wandeler, our new Chief Operating Officer. Roland was appointed to the MorphoSys management board and has joined the company three months ago. He leads our global commercial organization, including our U.S. operations. Roland will be available for the Q&A session after the presentation. Please move to slide five for the most recent and exciting highlight. As many of you will know, just a few days ago, on July 31, the FDA-approved Monjuvi as a combination therapy with lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma or DLBCL. We are very excited with the accelerated approval of Monjuvi by the FDA, which we believe emphasizes the high unmet need for these patients. This approval is a very important milestone, not only for MorphoSys, but also for patients battling this very aggressive disease as it is the first FDA-approved second-line therapy for adult patients with relapsed or refractory DLBCL. The clinical data in the FDA prescribing information demonstrate that